Operating to GMP & ICH Q7 standards across all manufacturing sites
Investor Relations Global Offices
Guide · 8 min read · By Global Biotech Laboratories Scientific Team · September 2026

A biotech startup’s guide to outsourcing peptide manufacturing

For a lean biotech, the right outsourcing strategy preserves capital and speed. Here is how to outsource peptide manufacturing without expensive missteps.

For most peptide startups, building in-house manufacturing makes no sense early on — it ties up capital and capacity you do not have. Outsourcing to the right partner preserves runway and speed. But outsourcing well is a skill. Here is how lean teams should approach it.

Why outsource (and when)

Outsourcing converts fixed costs into variable ones, gives you immediate access to expertise and equipment, and lets you focus on the science that differentiates you. For nearly every startup, a peptide CDMO is the right answer until volumes and certainty justify owning capacity.

What to outsource

  • Custom synthesis of research material to enable your biology (custom peptide synthesis).
  • Process & analytical development as you head toward the clinic.
  • GMP manufacturing and API supply for clinical and commercial use.

Choosing the right partner

The single most important decision is who you choose. Favor a partner who can grow with you — from research through GMP — under one quality system, so you are not re-transferring the process every phase. Our 12-point CDMO checklist and RFP template are built for exactly this decision.

Key point: choose for the company you will be in three years, not just the order you need today. Continuity with one partner usually beats a marginal price saving.

Plan across phases

Start with research-grade material, then move to GMP as you approach the clinic, planning the transition early to avoid re-work. Budget for the fact that GMP costs more and takes longer, and that cost and lead times rise with purity, scale and complexity.

Common mistakes to avoid

  • Choosing on price alone, then paying for it in delays.
  • Switching suppliers at the same time as scaling up.
  • Over-specifying purity or grade for the stage.
  • Engaging too late, so capacity is not available when you need it.
FAQ

Outsourcing — common questions.

Should a biotech startup outsource peptide manufacturing?

For most startups, yes. Outsourcing to a peptide CDMO converts fixed costs into variable ones, gives immediate access to expertise and equipment, and preserves capital and focus until volumes justify owning capacity.

What should a startup look for in a peptide CDMO?

Look for a partner that can grow with you from research through GMP under one quality system, with strong quality, analytics, regulatory support and honest lead times — so you avoid re-transferring the process at every phase.

What are common outsourcing mistakes startups make?

Choosing on price alone, switching suppliers while also scaling up, over-specifying purity or grade for the stage, and engaging a CDMO too late to secure capacity are the most common and costly mistakes.

Partner With Us

Building a peptide startup?

Tell us about your program and our team will respond within one business day.